Navigation LinksBiology NewsHealth NewsBiology TechnologyMedicine Technology


We're sorry, that page (http://www.bio-medicine.org/medicine-news-1/pdi--inc--announces-new-business-wins-exceeding--2418-million-48879-1/;+health+history;+medical+history.html) was not found.

Search medicine news 1 pdi inc announces new business wins exceeding 2418 million 48879 1 ;+health+history;+medical+history html at Google

Search medicine news 1 pdi inc announces new business wins exceeding 2418 million 48879 1 ;+health+history;+medical+history html at Yahoo

Search medicine news 1 pdi inc announces new business wins exceeding 2418 million 48879 1 ;+health+history;+medical+history html at Msn

Google
 
(Date:12/4/2009)... widely used by physicians and scientists to study brain ... remained largely unknown whether the electrodes on the head ... the brain. Scientists at the Max Planck Institute for ... crucial link between the activity generated within the brain ...
(Date:12/4/2009)... amyloids the fibrous protein deposits associated with diseases such ... potential new area for therapeutics. , It was believed that ... known as fibres - are inert, but that there may ... and cause disease. , But in a paper published ...
(Date:12/3/2009)... to changes in our daily environment, as well as to ... where nerve cells communicate, according to a new study by ... this week in the journal Nature . , ... physiology and neuroscience at NYU School of Medicine, discovered that ...
Breaking Biology News(10 mins):How to read brain activity? 2New therapy targets for amyloid disease 2Lifelong memories linked to stable nerve connections 2Health Insurance Options for Domestic Partnerships 51188 1Health Insurance Options for Domestic Partnerships 51188 2Health Insurance Options for Domestic Partnerships 51188 3Help For Handicapped From New Company 51187 1Amylin Pharmaceuticals Announces Positive Results from Dose Ranging Clinical Study of Pramlintide Metreleptin Combination Treatment for Obesity 12950 1Amylin Pharmaceuticals Announces Positive Results from Dose Ranging Clinical Study of Pramlintide Metreleptin Combination Treatment for Obesity 12950 2Amylin Pharmaceuticals Announces Positive Results from Dose Ranging Clinical Study of Pramlintide Metreleptin Combination Treatment for Obesity 12950 3Amylin Pharmaceuticals Announces Positive Results from Dose Ranging Clinical Study of Pramlintide Metreleptin Combination Treatment for Obesity 12950 4Amylin Pharmaceuticals Announces Positive Results from Dose Ranging Clinical Study of Pramlintide Metreleptin Combination Treatment for Obesity 12950 5
(Date:12/6/2009)... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today ... 2b 003-A1 study, known as the 003 trial, ... relapsed and refractory multiple myeloma patients. These data ... at the 51st annual meeting of the American ... in this trial is complete (n=269), and full ...
(Date:12/6/2009)... Sickle cell disease, a condition characterized ... one of the most common genetic blood disorders ... more than 70,000 Americans.(1) Research presented today at ... of Hematology highlights intriguing studies on the acute ... with this blood disorder, evaluations of both new ...
(Date:12/6/2009)... Blood clotting, or coagulation, is an important process ... is injured. Sometimes, however, clots form on the ... do not dissolve naturally, a potentially life-threatening situation ... Annual Meeting of the American Society of Hematology ... aspirin and heparin with the hope of preventing ...
(Date:12/6/2009)... 2009 A new study provides welcome news for ... thromboembolism (VTE). , The condition is estimated to ... occurs when an abnormal clot forms in a vein ... swelling. In some cases, the clot may detach from ... to the lungs, causing a potentially fatal condition known ...
(Date:12/6/2009)... Disorders information and Treatment site www.sleeping-with-a-sleeping-disorder.com ... with herbal or natural sleep aids from around ... for a good cause. The submissions will be ... Aids ,Encyclopedia, by YOU, to be sold from ... will donate 100% of the proceeds ,from sales ...
Breaking Medicine News(10 mins):Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 3Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 4Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 6Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 7Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 8Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 9Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 3Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 4Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 5Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 6Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 7Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2
Request Info...
Form: Ready to use Applications: Western Blot, ELISA...
This kit only detects beta-galactosidase activity at pH 6 in cultured cells andtissue sections. Beta-galactosidase activity at pH 6 ispresent only in senescent cells, and is not found inpresenescent...
For the quantitative determination of cyclic AMP (cAMP) concentrations in cell culture supernates, serum, plasma, saliva, urine and cell lysates....
Biology Products:
Microwell-EIA for the detection of Insulin Autoantibody....
... color touch screen shows you the ... cassette it is ready-to-go in any ... assures accurate calibration prior to each ... with a removable, rechargeable battery, which ...
... sets the standard for testing blood ... at your patient's side - the ... self contained system can easily be ... ICU, or wherever you need it ...
... Platelet Agitators feature sturdy, ... non-slip texture coating and ... for your platelets. Helmer ... be used in Helmer ...
Medicine Products:
(Date:12/6/2009)... Conn., Dec. 6 Boehringer Ingelheim today ... etexilate (150 mg BID), a direct thrombin inhibitor ... acute VTE. Results of the trial were ... Annual Meeting and simultaneously published online in the ... ,, Dabigatran etexilate met the primary outcome of ...
(Date:12/4/2009)... Technology (NIST) and the Naval Research Laboratory have developed ... semiconductor crystal by prodding it with a scanning tunneling ... will enable researchers to selectively implant atoms in a ... electrical and magnetic properties on the atomic scale. , ...
(Date:12/4/2009)... Iowa, Dec. 4 Vivakor, Inc. (OTC Bulletin Board: ... December 1, 2009 will receive the dividend of shares ... approved by Vivakor,s Board of Directors. HealthAmerica is ... 84% of the outstanding common shares on the record ...
(Date:12/4/2009)... Advanced Micro Nano Technology Products (ACAMP) hosts, ... Dec. 4 /PRNewswire/ - Today ACAMP hosted a ... nanotechnology, biomaterials and microfluidics can play a powerful ... that help promote health and improve the quality, ...
Breaking Biology Technology:RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6NIST researchers put a new spin on atomic musical chairs 2Vivakor Confirms Record Date of Stock Dividend 2Vivakor Confirms Record Date of Stock Dividend 3Alberta companies delivering new products to the health & medical marketplace 2
(Date:12/4/2009)... today announced the three grand prize winners of Bayer,s "Express ... Brothers, selected the winning video entries submitted by children with ... in-person meeting today with Nick. ,, The winners, ... 6, from Danbury, CT, who dreams of becoming a major ...
(Date:12/4/2009)... WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: ... Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine ... antidepressants in adults with Major Depressive Disorder (MDD). SEROQUEL ... by the FDA to treat both major depressive disorder ...
(Date:12/3/2009)... ACTON, Mass., Dec. 3 Allen Medical Systems, a ... ), today announced the launch of its new Allen ... www.AllenAmatech.com . ,, The website reinforces the ... of the new product catalog, with detailed descriptions and ...
Breaking Medicine Technology:Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website 2TeamPraxis Finishes Strong First Year of National Sales 51185 1TeamPraxis Finishes Strong First Year of National Sales 51185 2TeamPraxis Finishes Strong First Year of National Sales 51185 3TeamPraxis Finishes Strong First Year of National Sales 51185 4TeamPraxis Finishes Strong First Year of National Sales 51185 5Statement by Registered Dietitian and American Dietetic Association President Jessie M Pavlinac on Health Reform and Conservation of Natural Resource 51184 1Statement by Registered Dietitian and American Dietetic Association President Jessie M Pavlinac on Health Reform and Conservation of Natural Resource 51184 2Genoptix Inc to Announce Second Quarter 2009 Financial Results 51182 1Genoptix Inc to Announce Second Quarter 2009 Financial Results 51182 2